Efficacy and Safety of Sugammadex in Thoracoscopy Thymectomy for Chinese Adults With Myasthenia Gravis
Launched by BEIJING TONGREN HOSPITAL · May 24, 2024
Trial Information
Current as of February 08, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness and safety of a medication called sugammadex in helping patients with myasthenia gravis (MG) recover from anesthesia during a specific surgery called thoracoscopic thymectomy. The trial compares sugammadex to another medication, neostigmine, to see which one helps patients recover faster from muscle relaxation caused by anesthesia. A total of 64 patients aged 18 to 65 years with MG who are scheduled for this surgery can participate.
During the trial, patients will be randomly divided into two groups – one group will receive sugammadex, while the other will receive neostigmine. Both groups will undergo the same surgical and anesthesia procedures. Researchers will measure how quickly patients recover their muscle function and any potential side effects after taking the medications. This trial is important because finding the best way to help patients recover from anesthesia can improve their overall experience and safety during and after surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • Patients with MG scheduled for elective thoracoscopic thymectomy
- • Aged 18 to 65 years
- • American society of Anesthesiologists (ASA) physical status classification system: I - III
- Exclusion Criteria:
- • Inability to obtain written informed consent
- • With severe renal or hepatic dysfunction
- • A plan to return to ICU with intubation postoperation
- • A family history of malignant hyperthermia
- • Suspected difficult airway
- • Allergy to medications involved in the study
- • A contraindication for neostigmine or sugammadex administration
- • The patient's arm is not available for neuromuscular monitoring
- • Patients receiving medication known to interfere with NMBAs (e.g., anticonvulsants, antibiotics, magnesium salts)
- • Pregnant or lactating patients
Trial Officials
Guyan Wang
Study Director
Beijing Tongren Hospital
About Beijing Tongren Hospital
Beijing Tongren Hospital, affiliated with Capital Medical University, is a leading medical institution in China known for its comprehensive clinical services and research initiatives. With a strong focus on ophthalmology and a commitment to advancing healthcare through innovative clinical trials, the hospital leverages its expertise in various specialties to contribute to medical knowledge and improve patient outcomes. The institution is dedicated to adhering to the highest ethical standards and regulatory requirements, ensuring the integrity and reliability of its research endeavors. Through collaboration with national and international partners, Beijing Tongren Hospital aims to enhance the quality of care and foster advancements in medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nanjing, Jiangsu, China
Beijing, Beijing, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0